Xencor, Inc Contract with Customer, Receivable, after Allowance for Credit Loss
Xencor, Inc (XNCR) had Contract with Customer, Receivable, after Allowance for Credit Loss of $42.23 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Receivable, after Allowance for Credit Loss $42.23M.
- 2026-03-31: Contract with Customer, Receivable, after Allowance for Credit Loss $12.00M.
- 2025-12-31: Contract with Customer, Receivable, after Allowance for Credit Loss $29.30M.
- 2025-06-30: Contract with Customer, Receivable, after Allowance for Credit Loss $45.36M.
| Period end | Contract with Customer, Receivable, after Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $42.23M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $12.00M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $29.30M 10-K · filed 2026-02-25 |
| 2025-06-30 | $45.36M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $33.85M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $53.55M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |